{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Diagnostics & Research news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/diagnostics-research/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/diagnostics-research/feed.json", "description": "Latest Diagnostics & Research company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "watch:6b8383dc-d76a-493b-a91b-12f155ca0a51", "url": "https://sharemaestro.com/market-watch/natera-ntra-weekly-surge-322-close/", "external_url": null, "title": "Natera Inc (NTRA) closes at $322.10 after 20.3% weekly surge", "content_text": "The diagnostics stock\u2019s latest weekly move extended a sharp three-month advance, with turnover running above its recent average.", "date_published": "2026-08-14T15:14:53.917779+00:00", "authors": [{"name": "Sharemaestro Market Watch"}], "tags": ["Weekly signal", "NTRA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NTRA", "name": "Natera Inc", "sentiment_url": "https://sharemaestro.com/sentiment/125f8cfb-18df-4bd2-a1a4-c526de810e9b/"}]}}, {"id": "source:97c858d35b442adeaa8782f828f3b3b4247965e763be76be63826112f55ef2e8", "url": "https://www.stocktitan.net/sec-filings/DGX/schedule-13g-a-quest-diagnostics-inc-amended-passive-investment-discl-c70a833ad4c8.html", "external_url": "https://www.stocktitan.net/sec-filings/DGX/schedule-13g-a-quest-diagnostics-inc-amended-passive-investment-discl-c70a833ad4c8.html", "title": "T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A", "content_text": "T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly denying beneficial ownership. This filing provides key figures on their holdings and control over Quest Diagnostics shares.", "date_published": "2026-08-14T14:39:51+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "DGX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DGX", "name": "Quest Diagnostics Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/e6a96f2d-1f29-46d8-a1e2-57c92ab8ff92/"}]}}, {"id": "source:248efd7b0396e455702198e5194d740438aa7b88a4d03f1dc91e1f93d1f33f1b", "url": "https://www.investing.com/news/sec-filings/labcorp-announces-executive-leadership-changes-effective-in-september-93CH-4860896", "external_url": "https://www.investing.com/news/sec-filings/labcorp-announces-executive-leadership-changes-effective-in-september-93CH-4860896", "title": "Labcorp announces executive leadership changes effective in September", "content_text": "Labcorp (NYSE:LH) has announced executive leadership changes effective in September. Megan D. Bailey is resigning as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., will assume an expanded role as Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, responsible for both Early Development Research Laboratories and Central Laboratories businesses, effective September 1, 2026. The company also recently reported strong second-quarter results, surpassing Wall Street expectations, with adjusted earnings of $4.99 per share and revenue of $3.73 billion, and has raised its full-year outlook.", "date_published": "2026-08-14T14:04:33+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "LH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LH", "name": "Laboratory Corporation of America Holdings", "sentiment_url": "https://sharemaestro.com/sentiment/85aa6122-bac1-42e4-9d40-29c4d3d605d0/"}]}}, {"id": "source:7ba1d3628a22e20904f590ae55776bd8abc7a9e5c7beffe9727b8a9ba60ce42c", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales", "content_text": "Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales", "date_published": "2026-08-14T12:46:29+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Balance sheet", "NTRA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NTRA", "name": "Natera Inc", "sentiment_url": "https://sharemaestro.com/sentiment/125f8cfb-18df-4bd2-a1a4-c526de810e9b/"}]}}, {"id": "source:830070169b6bb69b064a4ed30cb244706b616273074d7de5e549e69dae8f2248", "url": "https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-94722b0d78ba.html", "external_url": "https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-94722b0d78ba.html", "title": "Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G", "content_text": "EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own these shares, with holdings representing 5% or less of the class. EdgePoint holds sole voting and dispositive power over 1,945,483 shares, and shared power over 576,152 shares.", "date_published": "2026-08-14T12:43:35+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "TWST"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TWST", "name": "Twist Bioscience Corp", "sentiment_url": "https://sharemaestro.com/sentiment/869ebde0-6a03-4e36-bf0e-afe9f9df4ec0/"}]}}, {"id": "source:40e21c9315ff980ca9d06825f999588cd338ebb507848bdce38242ea67a537f1", "url": "https://www.marketbeat.com/instant-alerts/filing-brown-shipley-co-ltd-acquires-new-shares-in-thermo-fisher-scientific-inc-tmo-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-brown-shipley-co-ltd-acquires-new-shares-in-thermo-fisher-scientific-inc-tmo-2026-08-14", "title": "Brown Shipley& Co Ltd Acquires New Shares in Thermo Fisher Scientific Inc. $TMO", "content_text": "Brown Shipley & Co Ltd has acquired 10,509 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $5.27 million, making it their 11th largest holding. Thermo Fisher Scientific recently reported strong quarterly earnings, exceeding analyst estimates with an EPS of $6.03 and revenue of $11.99 billion, and provided positive fiscal 2026 EPS guidance. The company also declared a quarterly dividend of $0.47 per share, and analysts generally maintain a \"Moderate Buy\" rating with an average price target of $619.41.", "date_published": "2026-08-14T08:17:29+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:31fd510cd7b7976e68e97b9c8070480fac80d6fe1d9192ebed24e7280fc05de4", "url": "https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-acquires-4334-shares-of-quest-diagnostics-incorporated-dgx-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-acquires-4334-shares-of-quest-diagnostics-incorporated-dgx-2026-08-14", "title": "Assenagon Asset Management S.A. Acquires 4,334 Shares of Quest Diagnostics Incorporated $DGX", "content_text": "Assenagon Asset Management S.A. increased its stake in Quest Diagnostics Incorporated by 39.1% in the second quarter, acquiring 4,334 shares and bringing its total holdings to 15,405 shares valued at approximately $3.27 million. The medical research company reported strong Q2 earnings, exceeding estimates with $3.12 EPS and a 10.2% revenue increase, and issued positive fiscal 2026 EPS guidance. Analysts currently maintain a \"Moderate Buy\" consensus rating for Quest Diagnostics.", "date_published": "2026-08-14T07:42:42+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "DGX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DGX", "name": "Quest Diagnostics Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/e6a96f2d-1f29-46d8-a1e2-57c92ab8ff92/"}]}}, {"id": "source:4508e01cb2b031a72ab24309b3e1143e04c24cf1075e5736f5e1b87baea8dd93", "url": "https://biopharmaapac.com/news/18/8319/thermo-fisher-scientific-and-kyan-technologies-sign-mou-to-advance-functional-precision-oncology-for-solid-tumours.html", "external_url": "https://biopharmaapac.com/news/18/8319/thermo-fisher-scientific-and-kyan-technologies-sign-mou-to-advance-functional-precision-oncology-for-solid-tumours.html", "title": "Thermo Fisher Scientific and KYAN Technologies Sign MoU to Advance Functional Precision Oncology for Solid Tumours", "content_text": "Thermo Fisher Scientific and KYAN Technologies have signed an MoU to advance functional precision oncology for solid tumours. The collaboration will use patient-derived tumoroid models, functional drug-response screening, and genomic analysis to gather patient-relevant data across various cancers, aiming to improve therapeutic decision-making. They will integrate Thermo Fisher's Gibco\u2122 OncoPro\u2122 Tumoroid Culture Medium and NGS technologies with KYAN's Optim.AI\u2122 platform to create a comprehensive workflow for evaluating tumor biology and treatment responses.", "date_published": "2026-08-14T07:29:26+00:00", "authors": [{"name": "BioPharma APAC"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:cf8f8e2e6dfcace0e6fe8f5af3d77937351bfb2e3ce92051161d225e3ad41307", "url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "external_url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "title": "Envetec Appoints Patrick S. Jones as Independent Director", "content_text": "Envetec Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec's global expansion Patrick S. JonesPatrick S. Jones, President of Thermo Fisher Scientific's Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life sciences, today announced the appointment of Patrick S. Jones, president of Thermo Fisher Scientific", "date_published": "2026-08-14T07:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:ad16c0dcc5c054879b68dbf9ee0789677bce34096acf2d470b111860d16acb53", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-charles-060500474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-charles-060500474.html", "title": "5 Insightful Analyst Questions From Charles River Laboratories\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Charles River Laboratories's Q2 Earnings Call Charles River Laboratories' second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as critical factors ", "date_published": "2026-08-14T06:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:6ba57187e1a4c4b1e550c7fe3295a80b25c1edbd77839682ed42b1e0b736e0f4", "url": "https://www.pharmaceuticalonline.com/doc/mettler-toledo-introduces-lightningbuild-program-for-four-week-delivery-0001", "external_url": "https://www.pharmaceuticalonline.com/doc/mettler-toledo-introduces-lightningbuild-program-for-four-week-delivery-0001", "title": "METTLER TOLEDO Introduces LightningBuild Program For Four-Week Delivery", "content_text": "METTLER TOLEDO Product Inspection Group has launched its new LightningBuild program, offering a four-week delivery time for select product inspection systems. The program currently includes the X12 LightningBuild x-ray inspection system and the C31 LightningBuild checkweigher, designed to help food and pharmaceutical manufacturers quickly adapt to production needs. This initiative aims to address timing challenges in seasonal production and contract packaging by significantly reducing lead times.", "date_published": "2026-08-14T00:38:53+00:00", "authors": [{"name": "Pharmaceutical Online"}], "tags": ["Market update", "MTD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MTD", "name": "Mettler-Toledo International Inc", "sentiment_url": "https://sharemaestro.com/sentiment/5b771fab-ab57-4d66-890a-143eaf431b8b/"}]}}, {"id": "source:6d94a2828794f443fb7600fc36fdf927e9d2536c40861e5a870a9d6ffbb4958c", "url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "title": "Could Danaher Corporation (DHR)\u2019s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?", "content_text": "When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower in response. That drop immediately spilled over to Bio-Rad Laboratories, Inc. (NYSE:BIO), holder of a $5 billion strategic stake in Sartorius, sending Bio-Rad shares down about 1% in early New York trading.", "date_published": "2026-08-14T00:13:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DHR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DHR", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/87a62723-7ed3-4f58-bf60-d8284fd599db/"}]}}, {"id": "source:79212e353989d92c6c2e576e3b52190de23ee32f894f3b4fc366f728fbb02e5a", "url": "https://peprofessional.com/2026/08/astorg-cultures-a-new-diagnostics-company-from-thermo-fisher", "external_url": "https://peprofessional.com/2026/08/astorg-cultures-a-new-diagnostics-company-from-thermo-fisher", "title": "Astorg Cultures a New Diagnostics Company From Thermo Fisher", "content_text": "Astorg Partners has acquired Thermo Fisher Scientific's global microbiology business for $1.075 billion, creating an independent diagnostics company focused on microbial testing. The newly independent entity, which will operate under a new brand and CEO Dirk Bontridder, manufactures consumables and instruments for identifying and testing microbes, serving over 15,000 customers across hospital, food, and pharmaceutical sectors. This carve-out aims to capitalize on the growing $5.8 billion clinical microbiology diagnostics market, driven by rising antimicrobial resistance and increased demand for safety testing.", "date_published": "2026-08-13T22:48:10+00:00", "authors": [{"name": "Private Equity Professional"}], "tags": ["Deals and strategy", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "news:b42c6220-4aef-442c-94f0-ec40fc46a857", "url": "https://sharemaestro.com/news/guardant-health-77-percent-quarter-volume-cools/", "external_url": null, "title": "Guardant Health trades 4.6% below its high after a 77.5% quarter, while volume cools", "content_text": "The precision-oncology diagnostics stock remains in an active weekly Trend Signal, but lighter participation and a wide fair-value premium make confirmation the next test.", "date_published": "2026-08-13T22:14:24.176166+00:00", "authors": [{"name": "Sharemaestro News"}], "tags": ["Company research", "GH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GH", "name": "Guardant Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/a955950c-56d3-45f7-b803-cb42c2775d6e/"}]}}, {"id": "source:77b07ff157b524516713012318d88ad3ae9bdd7a101a203cbdd0218a156efbb9", "url": "https://www.quiverquant.com/news/Fund+Update%3A+3%2C029%2C037+THERMO+FISHER+SCIENTIFIC+%28TMO%29+shares+added+to+DODGE+%26+COX+portfolio", "external_url": "https://www.quiverquant.com/news/Fund+Update%3A+3%2C029%2C037+THERMO+FISHER+SCIENTIFIC+%28TMO%29+shares+added+to+DODGE+%26+COX+portfolio", "title": "Fund Update: 3,029,037 THERMO FISHER SCIENTIFIC (TMO) shares added to DODGE & COX portfolio", "content_text": "DODGE & COX has significantly increased its holdings in THERMO FISHER SCIENTIFIC (TMO) by adding 3,029,037 shares, as revealed in a recent SEC 13F filing for the Q2 2026 report period. This move comes amidst varied institutional investor activity, with some firms adding and others decreasing their positions in TMO. The article also details recent insider trading, government contracts, congressional stock trades, and analyst price targets for THERMO FISHER SCIENTIFIC.", "date_published": "2026-08-13T21:39:06+00:00", "authors": [{"name": "Quiver Quantitative"}], "tags": ["Analyst action", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:5e4ae324d41626281bc06163991b16b91087267b80af0de5951b0c846ea49de0", "url": "https://www.marketbeat.com/instant-alerts/birgit-girshick-sells-6500-shares-of-charles-river-laboratories-international-nysecrl-stock-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/birgit-girshick-sells-6500-shares-of-charles-river-laboratories-international-nysecrl-stock-2026-08-13", "title": "Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock", "content_text": "Birgit Girshick, CEO of Charles River Laboratories International (NYSE:CRL), sold 6,500 shares of the company's stock for approximately $1.82 million. This transaction, executed under a Rule 10b5-1 trading plan, reduced her ownership by 15.29%. The company recently reported strong quarterly EPS and revenue that beat consensus estimates but saw a year-over-year revenue decline, while analysts maintain a \"Moderate Buy\" rating with an average price target of $255.65.", "date_published": "2026-08-13T21:37:25+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:06bdf40bbb8a705494fc3fb64327eb90976cf16c942693694fda6d0c0b54d7d8", "url": "https://www.marketbeat.com/instant-alerts/charles-river-laboratories-international-nysecrl-evp-sells-103865724-in-stock-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/charles-river-laboratories-international-nysecrl-evp-sells-103865724-in-stock-2026-08-13", "title": "Charles River Laboratories International (NYSE:CRL) EVP Sells $1,038,657.24 in Stock", "content_text": "Charles River Laboratories International's EVP, Shannon Parisotto, sold 3,714 shares of company stock for approximately $1.04 million, reducing her holdings by 43.59%. This transaction was conducted under a pre-arranged Rule 10b5-1 plan. The company recently reported adjusted earnings of $3.02 per share, exceeding estimates, with revenue of $1 billion, and has maintained its fiscal 2026 EPS guidance.", "date_published": "2026-08-13T21:19:36+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:6ad6047cf36ec912a3ac84d6caa1998c52de65b26eb6abac6c5b812db49a8e50", "url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-underperforms-thursday-when-compared-to-competitors-fff351a5-1d77a9ad15dd?mod=goog_fin_scmw", "external_url": "https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-underperforms-thursday-when-compared-to-competitors-fff351a5-1d77a9ad15dd?mod=goog_fin_scmw", "title": "Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors", "content_text": "Charles River Laboratories International Inc. (CRL) stock fell 1.09% to $281.27 on Thursday, despite a positive trading session for the broader market. This underperformance snapped a seven-day winning streak for the company's shares. The S&P 500 Index rose 0.65%, and the Dow Jones Industrial Average gained 0.13% on the same day.", "date_published": "2026-08-13T21:13:36+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Market update", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:0bacc278f1c751d6b5adc5329802bb7c62753bbe54b32475ead0bd6a6f51a6cf", "url": "https://www.marketbeat.com/instant-alerts/michael-shafer-sells-25500-shares-of-thermo-fisher-scientific-nysetmo-stock-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/michael-shafer-sells-25500-shares-of-thermo-fisher-scientific-nysetmo-stock-2026-08-13", "title": "Michael Shafer Sells 25,500 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock", "content_text": "Michael Shafer, EVP of Thermo Fisher Scientific (NYSE:TMO), sold 25,500 shares of the company's stock for $15.3 million, reducing his direct holdings by 54.85%. This sale occurred via a pre-arranged Rule 10b5-1 trading plan. The transaction follows the company's stronger-than-expected quarterly results and a positive outlook from analysts, who maintain a \"Moderate Buy\" rating with an average price target of $619.41.", "date_published": "2026-08-13T21:12:08+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:f22b37bf5416ff0f622acb5ad077a188b6bd53836021c7c7ec4878a5152321ef", "url": "https://www.marketwatch.com/data-news/thermo-fisher-scientific-inc-stock-falls-thursday-underperforms-market-88a6ee47-b62a11023637?mod=goog_fin_scmw", "external_url": "https://www.marketwatch.com/data-news/thermo-fisher-scientific-inc-stock-falls-thursday-underperforms-market-88a6ee47-b62a11023637?mod=goog_fin_scmw", "title": "Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market", "content_text": "Thermo Fisher Scientific Inc. (TMO) saw its stock price fall by 1.18% on Thursday, closing at $595.89. This performance lagged behind the broader market, as the S&P 500 Index and the Dow Jones Industrial Average both posted gains. This marks the second consecutive day of losses for the company's stock.", "date_published": "2026-08-13T20:39:26+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:37d47839f42054279866e448954b5761125277a6c68d86e054cb0b7f95bfe083", "url": "https://www.stocktitan.net/sec-filings/CRL/form-4-charles-river-laboratories-international-inc-insider-trading-a-9b8dfe1a3cd1.html", "external_url": "https://www.stocktitan.net/sec-filings/CRL/form-4-charles-river-laboratories-international-inc-insider-trading-a-9b8dfe1a3cd1.html", "title": "Charles River Labs (CRL) CEO exercises 6,500 options and sells shares under 10b5-1 plan", "content_text": "Charles River Laboratories (CRL) CEO Birgit Girshick exercised stock options for 6,500 shares on August 11, 2026, at an exercise price of $179.66 per share. Simultaneously, she sold these 6,500 common shares at $279.90 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 3, 2025, and after the sale, Girshick holds 43,803 common shares indirectly through a revocable trust.", "date_published": "2026-08-13T20:38:36+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:f17e012939bd550c5f974951e195e0ab63719ee2ae9925986003b7c925a11f26", "url": "https://www.stocktitan.net/sec-filings/CRL/form-4-charles-river-laboratories-international-inc-insider-trading-a-8d1782ad59a2.html", "external_url": "https://www.stocktitan.net/sec-filings/CRL/form-4-charles-river-laboratories-international-inc-insider-trading-a-8d1782ad59a2.html", "title": "Charles River (CRL) executive Parisotto exercises options, sells 3,714 shares under 10b5-1 plan", "content_text": "Shannon M. Parisotto, CEVP, Discovery & Safety Assessment at Charles River Laboratories International, exercised stock options for 3,714 shares at $179.66 per share and simultaneously sold the same number of shares at $279.66 per share. These transactions, executed on August 11, 2026, were conducted under a Rule 10b5-1 Trading Plan adopted on March 4, 2026. Following these sales, Parisotto's indirect holdings include 9,680 shares in a trust and 28,510 shares held by Karpathos Investments LLC.", "date_published": "2026-08-13T20:37:32+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:a08d143299fadedc027eeb563cc363319ae398f0827b128d6c85872348b0e279", "url": "https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-2f31f848313c.html", "external_url": "https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-2f31f848313c.html", "title": "Artisan Partners group (TWST) discloses 4.8M-share position in Twist Bioscience", "content_text": "Artisan Partners Asset Management Inc. and its affiliates have disclosed a beneficial ownership of 4,802,017 common shares, representing a 7.7% stake, in Twist Bioscience Corporation (TWST). This position is held on behalf of Artisan Partners Limited Partnership's discretionary clients, with shared voting power over 4,215,805 shares and shared dispositive power over all 4,802,017 shares. The disclosure was made via a SCHEDULE 13G/A SEC filing, indicating a passive investment approach.", "date_published": "2026-08-13T20:11:34+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "TWST"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TWST", "name": "Twist Bioscience Corp", "sentiment_url": "https://sharemaestro.com/sentiment/869ebde0-6a03-4e36-bf0e-afe9f9df4ec0/"}]}}, {"id": "source:a2f1a647ed20191b323f5fe4d9b20f324e145c46e59f8ebb908c981eae4dd5dc", "url": "https://www.stocktitan.net/sec-filings/TMO/form-4-thermo-fisher-scientific-inc-insider-trading-activity-e712f5d3f0aa.html", "external_url": "https://www.stocktitan.net/sec-filings/TMO/form-4-thermo-fisher-scientific-inc-insider-trading-activity-e712f5d3f0aa.html", "title": "Thermo Fisher Scientific (TMO) EVP exercises options, then sells 25,500 shares", "content_text": "Michael D. Shafer, Executive Vice President at Thermo Fisher Scientific (TMO), exercised options for 25,500 shares of common stock at strike prices of $309.63 and $418.32 per share on August 11, 2026. Following the exercise, he sold all 25,500 shares at $600.00 per share, as part of a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. This transaction resulted in approximate gross sale proceeds of $15.30 million and an approximate pre-tax spread of $5.85 million.", "date_published": "2026-08-13T20:02:31+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:051411d3d8dd6539c1a01b38e19897f1aa508ef1116dec30e6c01f60cf39a5f2", "url": "https://www.tradingview.com/news/reuters.com,2026-08-13:newsml_PexJB8NQa:0-pta-dd-qiagen-n-v-managers-transactions-announcement-according-to-article-19-mar", "external_url": "https://www.tradingview.com/news/reuters.com,2026-08-13:newsml_PexJB8NQa:0-pta-dd-qiagen-n-v-managers-transactions-announcement-according-to-article-19-mar", "title": "PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR", "content_text": "This article announces a manager's transaction at QIAGEN N.V. involving Eva Pisa, a member of the administrative or supervisory body. The transaction is a retroactive adjustment for a February 2026 net share settlement, withholding an additional 544 shares to cover related taxes, and is linked to the exercise of share option programs. The transaction date was August 11, 2026, and it occurred outside a trading venue.", "date_published": "2026-08-13T19:41:25+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "QGEN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QGEN", "name": "Qiagen NV", "sentiment_url": "https://sharemaestro.com/sentiment/cc0b13dd-0d97-40b5-8d9c-692f14af49a3/"}]}}, {"id": "source:8aa075b08cd3ce838ce32b3f745f82e6751a927cb2ff79d1011d3595c0792005", "url": "https://finance.yahoo.com/healthcare/articles/qiagen-qgen-beat-own-guidance-191825052.html", "external_url": "https://finance.yahoo.com/healthcare/articles/qiagen-qgen-beat-own-guidance-191825052.html", "title": "Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?", "content_text": "Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a diagnostics and life sciences supplier still working through the loss of discontinued product lines, beating a cautious bar is one thing. What happens next, as management leans on a stack of new launches to carry the back half of the year, is the more interesting question.HPE Price Target Raised to $28 as Corporate AI Spending Accelerates Bull Ca", "date_published": "2026-08-13T19:18:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QGEN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QGEN", "name": "Qiagen NV", "sentiment_url": "https://sharemaestro.com/sentiment/cc0b13dd-0d97-40b5-8d9c-692f14af49a3/"}]}}, {"id": "source:ef4b327ddbd36fd1d2456ff6bc4f2b1bb997d028a257c549868f59471957581e", "url": "https://finance.yahoo.com/healthcare/articles/qiagen-qgen-beat-own-guidance-185048677.html", "external_url": "https://finance.yahoo.com/healthcare/articles/qiagen-qgen-beat-own-guidance-185048677.html", "title": "Strong Beats Mask Zillow\u2019s (Z) Restructuring And Headwinds", "content_text": "Zillow Group (NASDAQ:Z) delivered a second quarter that beat its own outlook on nearly every line, then turned around and eliminated jobs and reshuffled its leadership team. On the call held August 5, CEO Jeremy Wacksman and newly expanded COO and CFO Jeremy Hofmann laid out a business growing far faster than the housing market around it, alongside a restructuring meant to fund that growth. The two stories sitting side by side are worth pulling apart.Strong Beats Mask Zillow\u2019s (Z) Restructuring And Headwinds Bull Case: Growth Pillars Driving Strong Performance Q2 revenue rose 18% year-over-yea", "date_published": "2026-08-13T18:50:48+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QGEN"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "QGEN", "name": "Qiagen NV", "sentiment_url": "https://sharemaestro.com/sentiment/cc0b13dd-0d97-40b5-8d9c-692f14af49a3/"}]}}, {"id": "source:5933ea76d67811eadca2880c5efcebfeb4f343e56b775598cbdc31624dde9ff6", "url": "https://www.stocktitan.net/sec-filings/CRL/schedule-13g-charles-river-laboratories-international-inc-passive-inv-a4ad5014f7e4.html", "external_url": "https://www.stocktitan.net/sec-filings/CRL/schedule-13g-charles-river-laboratories-international-inc-passive-inv-a4ad5014f7e4.html", "title": "Invesco reports 2.98M-share stake in Charles River Laboratories (CRL)", "content_text": "Invesco Ltd., a Bermuda-based parent holding company, has reported a significant passive ownership position in Charles River Laboratories International, Inc. (CRL) common stock. The firm beneficially owns 2,984,785 shares, representing 6.2% of the outstanding common stock, held by its investment advisory clients. Invesco maintains sole voting power over 2,955,113 shares and sole dispositive power over all 2,984,785 shares, with no single underlying client holding more than 5% economic ownership.", "date_published": "2026-08-13T18:37:46+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "CRL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CRL", "name": "Charles River Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/1918e4cd-5d17-42c0-a068-f48122b68052/"}]}}, {"id": "source:5f8c1d134382c1b890a5afc7ba555877e0ca91e0b96c7c18dcd968a601272092", "url": "https://www.mondaq.com/pressrelease/205266/axinn-advises-thermo-fisher-scientific-on-completed-%241075-billion-sale-of-microbiology-business-to-astorg", "external_url": "https://www.mondaq.com/pressrelease/205266/axinn-advises-thermo-fisher-scientific-on-completed-%241075-billion-sale-of-microbiology-business-to-astorg", "title": "Axinn Advises Thermo Fisher Scientific On Completed $1.075 Billion Sale Of Microbiology Business To Astorg", "content_text": "Axinn advised Thermo Fisher Scientific Inc. (NYSE: TMO) on the completed sale of its microbiology business to Astorg, a private equity firm, for approximately $1.075 billion. The microbiology business specializes in antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical, and food safety testing. The Axinn team involved partners James Hunsberger and Mark Alexander, and associates Megan Walden, Taylor Aiello, and Leandra Ipi\u00f1a.", "date_published": "2026-08-13T18:10:36+00:00", "authors": [{"name": "Mondaq"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:034a2efb0da6ab626d5a4a486f635bc725de9c0e882f8f20037217a04b28fbfb", "url": "https://www.food-safety.com/articles/11729-mettler-toledo-introduces-rapid-inspection-systems-delivery-system", "external_url": "https://www.food-safety.com/articles/11729-mettler-toledo-introduces-rapid-inspection-systems-delivery-system", "title": "Mettler Toledo Introduces Rapid Inspection Systems Delivery System", "content_text": "Mettler Toledo Product Inspection Group has launched LightningBuild, a program offering select product inspection systems with a four-week delivery time. This initiative includes the X12 LightningBuild X-ray inspection system and the C31 LightningBuild checkweigher, aiming to help food and pharmaceutical manufacturers quickly adapt to changing production needs. The program is available at no extra charge in the U.S., Canada, and Latin America, with plans to expand to more product inspection models in the future.", "date_published": "2026-08-13T18:09:02+00:00", "authors": [{"name": "Food Safety Magazine"}], "tags": ["Market update", "MTD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MTD", "name": "Mettler-Toledo International Inc", "sentiment_url": "https://sharemaestro.com/sentiment/5b771fab-ab57-4d66-890a-143eaf431b8b/"}]}}, {"id": "source:fe57ea292a2cd7907fe5fc41cf6e7a1f0144c73a6fcb94ae3157430285cd7a7f", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-rvty-stock-looks-reasonable-on-cash-flow-yet-rich-on/amp", "external_url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-rvty-stock-looks-reasonable-on-cash-flow-yet-rich-on/amp", "title": "Revvity (RVTY) Stock Looks Reasonable On Cash Flow Yet Rich On Earnings", "content_text": "Revvity (RVTY) stock has seen a 34.1% decline over the past five years. While a Discounted Cash Flow (DCF) model suggests the shares are undervalued by 23.0% at $153 per share, earnings-based multiples indicate the stock is expensive, trading at a P/E of 55.4x compared to an industry average of 37.3x. The article highlights a mixed valuation picture, with cash flow models suggesting a bargain due to anticipated growth from new products like the SuperFlex prenatal screening system, but earnings multiples pointing to overvaluation.", "date_published": "2026-08-13T17:09:20+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Earnings", "RVTY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RVTY", "name": "Revvity Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/030ff1ee-9d5e-489a-8d22-240e23f58c70/"}]}}, {"id": "source:aed6200906da815c1106d6a7b7efb9b8ca7ae097b313b8d6fbb52cde7cb7f4fc", "url": "https://www.mpo-mag.com/breaking-news/veracyte-debuts-prosigna-breast-test-in-the-u-s", "external_url": "https://www.mpo-mag.com/breaking-news/veracyte-debuts-prosigna-breast-test-in-the-u-s", "title": "Veracyte Debuts Prosigna Breast Test in the U.S.", "content_text": "Veracyte Inc. has launched its Prosigna Breast Risk of Recurrence (ROR) test in the U.S. This genomic assay helps patients with early-stage hormone-receptor positive breast cancer determine their 10-year risk of distant recurrence, guiding personalized treatment decisions, including whether chemotherapy will be beneficial. The Prosigna test uniquely combines intrinsic subtypes, proliferation score, and clinical factors to offer comprehensive and prognostically accurate insights, particularly for high-risk populations.", "date_published": "2026-08-13T16:41:17+00:00", "authors": [{"name": "Medical Product Outsourcing"}], "tags": ["Market update", "VCYT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VCYT", "name": "Veracyte Inc", "sentiment_url": "https://sharemaestro.com/sentiment/4434bb49-ff36-4457-920e-6c23e0b7b742/"}]}}, {"id": "source:3231e9d977d1349565c6a4056a8ea4ff1a17d612388e2bb7977bf58d8ae2fa2d", "url": "https://www.medtechdive.com/news/thermo-fisher-closes-11b-sale-of-microbiology-unit-to-pe-firm/827811", "external_url": "https://www.medtechdive.com/news/thermo-fisher-closes-11b-sale-of-microbiology-unit-to-pe-firm/827811", "title": "Thermo Fisher closes $1.1B sale of microbiology unit to PE firm", "content_text": "Thermo Fisher Scientific has completed the sale of its microbiology unit to European private equity firm Astorg for $1.1 billion. The newly independent company will specialize in microbiology diagnostics, employing approximately 2,400 people across 13 global sites, and will be led by former PerkinElmer CEO Dirk Bontridder. This divestiture provides Thermo Fisher with capital to enhance shareholder value, while Astorg plans to accelerate innovation and strengthen the business's global market position.", "date_published": "2026-08-13T15:56:57+00:00", "authors": [{"name": "MedTech Dive"}], "tags": ["Deals and strategy", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:4c400ccdad10014b599f1a889681bcc546fd32b3386c10ee6f7499b08e7084ba", "url": "https://www.investing.com/news/company-news/opko-health-secures-125m-financing-backed-by-mazdutide-royalties-93CH-4858160", "external_url": "https://www.investing.com/news/company-news/opko-health-secures-125m-financing-backed-by-mazdutide-royalties-93CH-4858160", "title": "OPKO Health secures $125m financing backed by mazdutide royalties", "content_text": "OPKO Health Inc. has secured $125 million in senior secured notes through an expanded financing agreement with HealthCare Royalty, a business of KKR. This financing is backed by OPKO\u2019s royalty interests from its mazdutide license agreement with Eli Lilly and Company, with notes maturing in 2044. Mazdutide is commercialized in China by Innovent Biologics, and OPKO began receiving royalties in 2025.", "date_published": "2026-08-13T14:40:02+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Market update", "OPK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OPK", "name": "Opko Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/086ee816-c150-4932-a1b7-61fdc8793cde/"}]}}, {"id": "source:e839dba7cf434a6070e3d9a1df9e4f9189c819682160c01843dfed18f5b30ce0", "url": "https://www.investing.com/news/company-news/twist-bioscience-stock-hits-52week-high-at-12622-usd-93CH-4858195", "external_url": "https://www.investing.com/news/company-news/twist-bioscience-stock-hits-52week-high-at-12622-usd-93CH-4858195", "title": "Twist Bioscience stock hits 52-week high at 126.22 USD", "content_text": "Twist Bioscience stock reached a new 52-week high of $126.22, trading just 1% below this peak and marking a remarkable 440% surge from its 52-week low. The company also reported strong fiscal third-quarter 2026 revenues of $118.4 million, exceeding Wall Street estimates, although adjusted earnings showed a wider loss than anticipated. Despite the earnings miss, the consistent revenue growth and investor confidence have driven the stock's significant appreciation over the past year.", "date_published": "2026-08-13T14:11:34+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "TWST"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TWST", "name": "Twist Bioscience Corp", "sentiment_url": "https://sharemaestro.com/sentiment/869ebde0-6a03-4e36-bf0e-afe9f9df4ec0/"}]}}, {"id": "source:2b6774dd903fdaad6fe7119ac772e4b771e6882ab1a607785954398cd6c342ab", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/iqvia-holdings-stock-trades-around-242-as-investors-weigh-recent-earnings/69946108", "external_url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/iqvia-holdings-stock-trades-around-242-as-investors-weigh-recent-earnings/69946108", "title": "IQVIA Holdings stock trades around $242 as investors weigh recent earnings trend", "content_text": "IQVIA Holdings stock is currently trading around $242, maintaining a market capitalization close to $40 billion, despite recent quarterly earnings showing a softer trend. Investors are focusing on the company's valuation, which includes a P/E multiple in the low 30s, and its future growth prospects in the health data and clinical research sector. Upcoming earnings reports will be critical in determining whether the stock's current valuation is justified given the slower earnings momentum.", "date_published": "2026-08-13T14:10:00+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Earnings", "IQV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IQV", "name": "IQVIA Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ead67a1d-3331-46b9-962d-63392c114616/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "external_url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026. Per management, the SuperFlex system represents a significan", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RVTY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RVTY", "name": "Revvity Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/030ff1ee-9d5e-489a-8d22-240e23f58c70/"}]}}, {"id": "source:cc98824c570102764ebc45b415817348bfd41c205fbef7d6209f52885f744fcc", "url": "https://www.stocktitan.net/news/OPK/opko-health-expands-strategic-relationship-with-health-care-royalty-oxdbtjkzah2t.html", "external_url": "https://www.stocktitan.net/news/OPK/opko-health-expands-strategic-relationship-with-health-care-royalty-oxdbtjkzah2t.html", "title": "OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties", "content_text": "OPKO Health (NASDAQ: OPK) has expanded its financing relationship with HealthCare Royalty by issuing an additional $125 million in senior secured notes, backed by royalty interests from its mazdutide license with Eli Lilly. These notes mature in 2044, and the agreement caps total payments at 1.5 times the funded amount, allowing OPKO to retain future royalty economics thereafter. This move provides non-dilutive capital and strengthens the company's balance sheet while preserving long-term upside from the mazdutide franchise, which began generating royalty revenue in 2025 from commercialization in China by Innovent Biologics.", "date_published": "2026-08-13T13:40:02+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "OPK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OPK", "name": "Opko Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/086ee816-c150-4932-a1b7-61fdc8793cde/"}]}}, {"id": "source:cb06f6881a4ca0938732efe5068ee1c6a1d658b8fcc1c0e0dcadc224181ff274", "url": "https://www.opko.com/investors/news-events/press-releases/detail/550/opko-health-expands-strategic-relationship-with-healthcare-royalty-through-125-million-notes-issuance-secured-by-mazdutide-royalty-interests", "external_url": "https://www.opko.com/investors/news-events/press-releases/detail/550/opko-health-expands-strategic-relationship-with-healthcare-royalty-through-125-million-notes-issuance-secured-by-mazdutide-royalty-interests", "title": "OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests", "content_text": "OPKO Health has expanded its financing relationship with HealthCare Royalty (HCRx), a KKR business, by issuing an additional $125 million in senior secured notes. These notes are backed by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company, maturing in 2044. The transaction provides OPKO with non-dilutive capital, enhances financial flexibility, and preserves long-term royalty upside, as total payments are capped at 1.5 times the funded amount.", "date_published": "2026-08-13T13:40:02+00:00", "authors": [{"name": "OPKO Health, Inc."}], "tags": ["Market update", "OPK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OPK", "name": "Opko Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/086ee816-c150-4932-a1b7-61fdc8793cde/"}]}}, {"id": "source:23a89a8cc627819bfbee998a568a73aba3d7256da78117d5b25272b3548820a2", "url": "https://finance.yahoo.com/healthcare/articles/sotera-health-shc-q2-2026-132923797.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sotera-health-shc-q2-2026-132923797.html", "title": "Sotera Health (SHC) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Jason Peterson Executive Chairman - Michael Petras Chief Executive Officer - Alton Shader Chief Financial Officer - Jonathan Lyons Full Conference Call Transcript Operator: Good morning, and welcome to the Sotera Health Second Quarter 2026 Earnings Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations, Jason Peterson. Jason, please go ahead. Jason Peterson: Good", "date_published": "2026-08-13T13:29:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SHC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SHC", "name": "Sotera Health Co", "sentiment_url": "https://sharemaestro.com/sentiment/6291b368-5906-41fc-b8da-0168c3b248be/"}]}}, {"id": "source:c36e9fc54333e68024ff7b0d0e7db11f97296c03291cd9da3d7eac353a84edd1", "url": "https://www.tradingview.com/news/zacks:9b14eb6d5094b:0-national-vision-stock-down-despite-q2-earnings-revenue-beat", "external_url": "https://www.tradingview.com/news/zacks:9b14eb6d5094b:0-national-vision-stock-down-despite-q2-earnings-revenue-beat", "title": "National Vision Stock Down Despite Q2 Earnings & Revenue Beat", "content_text": "National Vision Holdings, Inc. reported stronger-than-expected Q2 2026 earnings and revenues, with adjusted earnings per share of 25 cents beating estimates by 47.1% and net revenues rising 2.5% year over year. Despite the beat and an expanded operating margin, the company's stock fell 7.9% following the announcement. National Vision also raised the lower end of its adjusted diluted earnings guidance for 2026, narrowing its comparable store sales growth outlook.", "date_published": "2026-08-13T13:12:58+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "DGX"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DGX", "name": "Quest Diagnostics Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/e6a96f2d-1f29-46d8-a1e2-57c92ab8ff92/"}]}}, {"id": "source:620d7ca60f04da9cddae9ebab54c8bed487820f996c5318be05ee40d5266672e", "url": "https://www.investorsinhealthcare.com/articles/category/news/luxembourg-dirk-bontridder-appointed-ceo-of-astorgs-microbiology-diagnostics-business-following-completion-of-acquisition-from-thermo-fisher-scientific", "external_url": "https://www.investorsinhealthcare.com/articles/category/news/luxembourg-dirk-bontridder-appointed-ceo-of-astorgs-microbiology-diagnostics-business-following-completion-of-acquisition-from-thermo-fisher-scientific", "title": "Luxembourg: Dirk Bontridder appointed CEO of Astorg\u2019s microbiology diagnostics business following completion of acquisition from Thermo Fisher Scientific", "content_text": "Dirk Bontridder has been appointed CEO of the newly independent microbiology diagnostics platform formed after Astorg completed its acquisition of Thermo Fisher Scientific's global microbiology business. Bontridder brings over 25 years of international leadership experience from the life sciences, diagnostics, and industrial technology sectors, having previously served as CEO of PerkinElmer. This acquisition, valued at US$1.075 billion, establishes a global platform serving clinical, food safety, and pharmaceutical markets, with the new company expected to launch under a new brand later in 2026.", "date_published": "2026-08-13T13:10:10+00:00", "authors": [{"name": "Investors in Healthcare"}], "tags": ["Deals and strategy", "TMO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "sentiment_url": "https://sharemaestro.com/sentiment/62392bd1-8921-4120-a935-b80f1ed83297/"}]}}, {"id": "source:7b3d2fc37fce59efe970f2fd40f13560e904c357d3ff9680577ba30c1670bbf6", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/agilent-technologies-stock-holds-steady-as-earnings-beat-and-new-analyst/69945552", "external_url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/agilent-technologies-stock-holds-steady-as-earnings-beat-and-new-analyst/69945552", "title": "Agilent Technologies stock holds steady as earnings beat and new analyst target support valuation", "content_text": "Agilent Technologies (A) stock is holding steady after reporting stronger-than-expected Q2 2026 earnings per share of $1.49 and 10% revenue growth to $1.83 billion. The company also issued fiscal 2026 EPS guidance between $6.00 and $6.10, which analysts anticipate will be around $6.01. A new analyst target of $175, up from $160, and a consensus target of $160.24, suggest continued confidence in the company's financial outlook, with the stock trading near its 52-week highs.", "date_published": "2026-08-13T12:54:57+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Earnings", "A"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A", "name": "Agilent Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/793178a6-33e6-4653-96a5-81c80d91b147/"}]}}, {"id": "source:f5e823d22d4f2e9d3f83590cb33a7f644d145de022aefcb342b87c6dd29ed090", "url": "https://www.stocktitan.net/news/CING/cingulate-inc-reports-second-quarter-2026-financial-results-and-wazdptey9215.html", "external_url": "https://www.stocktitan.net/news/CING/cingulate-inc-reports-second-quarter-2026-financial-results-and-wazdptey9215.html", "title": "Cingulate\u2019s ADHD Drug Patent Protects Its Formulation Through 2042", "content_text": "Cingulate Inc. reported its second-quarter 2026 financial results, highlighting $28.4 million in cash and cash equivalents, expected to fund operations into mid-2027. The company is advancing its CTx-1301 ADHD drug toward NDA resubmission following an FDA Complete Response Letter and secured a new U.S. patent extending protection for CTx-1301's formulation until December 2042. Commercialization efforts are underway, including distribution agreements and market access strategies, despite an increased net loss driven by higher SG&A expenses.", "date_published": "2026-08-13T12:39:54+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "IQV"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "IQV", "name": "IQVIA Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ead67a1d-3331-46b9-962d-63392c114616/"}]}}, {"id": "source:b0c8b42e3a3268c2ad3379b8bd3ba8147e4c84fb6bb975ead504c34703924938", "url": "https://www.tradingview.com/news/zacks:6ff8ada1f094b:0-tech-q4-earnings-meet-estimates-revenues-surpass-stock-rises", "external_url": "https://www.tradingview.com/news/zacks:6ff8ada1f094b:0-tech-q4-earnings-meet-estimates-revenues-surpass-stock-rises", "title": "TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises", "content_text": "Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting Zacks Consensus Estimates, while net sales of $321.2 million surpassed expectations. Despite some mixed segment performances and a contraction in adjusted gross margin, the company's shares rose slightly. The article also highlights Bio-Techne's agreement to be acquired by Merck KGaA for approximately $11.3 billion, which is progressing.", "date_published": "2026-08-13T12:39:26+00:00", "authors": [{"name": "TradingView"}], "tags": ["Deals and strategy", "DGX", "LH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DGX", "name": "Quest Diagnostics Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/e6a96f2d-1f29-46d8-a1e2-57c92ab8ff92/"}, {"symbol": "LH", "name": "Laboratory Corporation of America Holdings", "sentiment_url": "https://sharemaestro.com/sentiment/85aa6122-bac1-42e4-9d40-29c4d3d605d0/"}]}}, {"id": "source:cb6ff7536c44ea9941157f4f0b5fe2abd77f64f6f6798bbd32b97a1364e79340", "url": "https://finance.yahoo.com/technology/ai/articles/check-cap-mbai-advances-merger-123500429.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/check-cap-mbai-advances-merger-123500429.html", "title": "Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective", "content_text": "Check-Cap Ltd. (NASDAQ: MBAI) advanced its proposed merger with physical AI company, MBody AI Corp., completing a planned 1-for-7 reverse share split ISFIYA, Israel and LAS VEGAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (\"Check-Cap\" or the \"Company\") (NASDAQ: MBAI) today announced that a 1-for-7 reverse share split (the \"Reverse Share Split\") of the Company's ordinary shares is effective on August 13, 2026, advancing its proposed merger (\"the Merger\") with a physical AI company, MBody AI Corp. (\"MBody AI\"). The Company's ordinary shares begin trading on a split-adjusted basis on The N", "date_published": "2026-08-13T12:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "MBAI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MBAI", "name": "Check-Cap Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/515749f8-296a-4d47-9115-e14621d5f11a/"}]}}, {"id": "source:bc28a49ce510ac5a9ebb23de8819886b9b24d2f299e044b25775aab004164d6e", "url": "https://finance.yahoo.com/healthcare/articles/fda-clearance-qiastat-dx-bloodstream-121034829.html", "external_url": "https://finance.yahoo.com/healthcare/articles/fda-clearance-qiastat-dx-bloodstream-121034829.html", "title": "Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?", "content_text": "Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. On August 10, 2026, the company also secured U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, moving its QIAstat-Dx platform into bloodstream infection diagnostics and reinforcing its effort to offer a broad infectious disease testing menu on one integrated system. We'll now e", "date_published": "2026-08-13T12:10:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QGEN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QGEN", "name": "Qiagen NV", "sentiment_url": "https://sharemaestro.com/sentiment/cc0b13dd-0d97-40b5-8d9c-692f14af49a3/"}]}}, {"id": "source:8255e7cf86fc7f7dbf20ba8b05ab36ba147b66fe9dbd15078d59bb275410c8da", "url": "https://finance.yahoo.com/markets/stocks/articles/3-large-cap-stocks-risky-120500749.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/3-large-cap-stocks-risky-120500749.html", "title": "3 Large-Cap Stocks We Find Risky", "content_text": "3 Large-Cap Stocks We Find Risky Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they've already captured significant portions of their markets. This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. Keeping that in mind, here are three large-cap stocks whose momentum may slow and a few alternatives yo", "date_published": "2026-08-13T12:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DHR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DHR", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/87a62723-7ed3-4f58-bf60-d8284fd599db/"}]}}, {"id": "source:6a718becf991eeeaf34cd79c446bedd27ee9e3434e04d0e0d2465e2556e48a95", "url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "external_url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "title": "This Healthcare Services Stock Has 37% Upside", "content_text": "Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July\u2019s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%. Continue Reading", "date_published": "2026-08-13T12:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IQV"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "IQV", "name": "IQVIA Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ead67a1d-3331-46b9-962d-63392c114616/"}]}}, {"id": "source:fdc435ca0bb04a8a25780d1500b5a2b572147e339ee9c45ce24ef08d1adcb216", "url": "https://www.marketbeat.com/instant-alerts/quest-diagnostics-incorporated-nysedgx-plans-quarterly-dividend-of-086-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/quest-diagnostics-incorporated-nysedgx-plans-quarterly-dividend-of-086-2026-08-13", "title": "Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86", "content_text": "Quest Diagnostics (NYSE:DGX) has declared a quarterly dividend of $0.86 per share, payable on October 21st to shareholders of record on October 6th. This dividend represents an annualized payout of $3.44 and a 1.4% yield. The company has a strong dividend history, having increased its dividend for 14 consecutive years, and analysts project its earnings will sufficiently cover future payouts.", "date_published": "2026-08-13T11:56:52+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "DGX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DGX", "name": "Quest Diagnostics Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/e6a96f2d-1f29-46d8-a1e2-57c92ab8ff92/"}]}}]}